This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diagnosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • measurement of ANCA titre:
    • about 50-70% of patients have ANCA (1)
      • the ANCA found in microscopic polyangiitis is usually p-ANCA (directed to myeloperoxidase (MPO)) (1) - MPO-ANCA give a perinuclear staining pattern on immunofluorescence.
        • MPO-ANCA are found in microscopic polyangiitis (70%) but PR3-ANCA (ANCA directed against proteinase 3 giving a granular cytoplasmic staining pattern on immunofluorescence) can also occur (2)

  • renal biopsy
    • extracapillary glomerulonephritis is a feature in 90% of cases
      • similar findings to those seen in Wegener's granulomatosis but no granulomata are found

Notes:

  • the relative prevalences of cANCA and pANCA vary with different reviews. Jennette JC et al state that serologically, the prevalence of ANCA is anti-MPO pANCA 50% and anti-PR3 cANCA 40%, with negative results in 10% (3)

Reference:

  • (1) Bosch X et al. Antineutrophil cytoplasmic antibodies. The Lancet 2006;368 (9533): 404-418.
  • (2) Harper L, Weidanx F. Small vessel vasculitides. Medicine 2006; 34 (11): 456-463.
  • (3) Jennette JC et al. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol 2001;18: 3–13.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.